Abhay Gupta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7994730/publications.pdf

Version: 2024-02-01

27	661	687363	580821
papers	citations	13 h-index	25 g-index

29	29	29	604
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Real-time near-infrared monitoring of content uniformity, moisture content, compact density, tensile strength, and young's modulus of roller compacted powder blends. Journal of Pharmaceutical Sciences, 2005, 94, 1589-1597.	3.3	92
2	Nondestructive measurements of the compact strength and the particle-size distribution after milling of roller compacted powders by near-infrared spectroscopy. Journal of Pharmaceutical Sciences, 2004, 93, 1047-1053.	3.3	74
3	Real-time on-line blend uniformity monitoring using near-infrared reflectance spectrometry: A noninvasive off-line calibration approach. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 48-54.	2.8	68
4	Influence of Ambient Moisture on the Compaction Behavior of Microcrystalline Cellulose Powder Undergoing Uni-Axial Compression and Roller-Compaction: A Comparative Study Using Near-Infrared Spectroscopy. Journal of Pharmaceutical Sciences, 2005, 94, 2301-2313.	3.3	67
5	Development and application of a validated HPLC method for the determination of gabapentin and its major degradation impurity in drug products. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1647-1653.	2.8	47
6	Influence of Formulation and Processing Factors on Stability of Levothyroxine Sodium Pentahydrate. AAPS PharmSciTech, 2010, 11, 818-825.	3.3	46
7	Disintegration of Highly Soluble Immediate Release Tablets: A Surrogate for Dissolution. AAPS PharmSciTech, 2009, 10, 495-499.	3.3	33
8	Development and application of a validated HPLC method for the analysis of dissolution samples of gabapentin drug products. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 181-186.	2.8	32
9	Effect Of the Variation in the Ambient Moisture on the Compaction Behavior of Powder Undergoing Roller-Compaction And On The Characteristics Of Tablets Produced From The Post-Milled Granules. Journal of Pharmaceutical Sciences, 2005, 94, 2314-2326.	3.3	25
10	United States Food and Drug Administration and Department of Defense Shelf-Life Extension Program of Pharmaceutical Products: Progress and Promise. Journal of Pharmaceutical Sciences, 2014, 103, 1331-1336.	3.3	24
11	Comparison of the stability of split and intact gabapentin tablets. International Journal of Pharmaceutics, 2008, 350, 65-69.	5.2	19
12	Stability of gabapentin 300-mg capsules repackaged in unit dose containers. American Journal of Health-System Pharmacy, 2009, 66, 1376-1380.	1.0	15
13	Influence of tablet characteristics on weight variability and weight loss in split tablets. American Journal of Health-System Pharmacy, 2008, 65, 2326-2328.	1.0	13
14	Comparative stability of repackaged metoprolol tartrate tablets. International Journal of Pharmaceutics, 2010, 385, 92-97.	5.2	13
15	Challenges of pediatric formulations: A FDA science perspective. International Journal of Pharmaceutics, 2013, 457, 346-348.	5.2	12
16	Functionality of magnesium stearate derived from bovine and vegetable sources: Dry granulated tablets. Journal of Pharmaceutical Sciences, 2008, 97, 5328-5340.	3.3	11
17	Difference in the Lubrication Efficiency of Bovine and Vegetable-Derived Magnesium Stearate During Tabletting. AAPS PharmSciTech, 2009, 10, 500-504.	3.3	10
18	Development and Validation of a HPLC Method for Dissolution and Stability Assay of Liquid-Filled Cyclosporine Capsule Drug Products. AAPS PharmSciTech, 2013, 14, 959-967.	3.3	10

#	Article	IF	Citations
19	Dose Uniformity of Scored and Unscored Tablets: Application of the FDA Tablet Scoring Guidance for Industry. PDA Journal of Pharmaceutical Science and Technology, 2016, 70, 523-532.	0.5	10
20	Process Analytical Technology to Understand the Disintegration Behavior of Alendronate Sodium Tablets. Journal of Pharmaceutical Sciences, 2013, 102, 1513-1523.	3.3	9
21	Dose Uniformity of Scored and Unscored Tablets: Application of the FDA Tablet Scoring Guidance for Industry. PDA Journal of Pharmaceutical Science and Technology, 2016, 70, 523-532.	0.5	9
22	Regulatory Considerations in Development of Amorphous Solid Dispersions. Advances in Delivery Science and Technology, 2014, , 545-563.	0.4	7
23	Analytical Methods for the Evaluation of Melamine Contamination. Journal of Pharmaceutical Sciences, 2014, 103, 539-544.	3.3	5
24	FDA: Contribution to developing pediatric formulations and transatlantic collaboration. International Journal of Pharmaceutics, 2012, 435, 146-148.	5.2	2
25	Development and Application of a Validated HPLC Method for the Determination of Clindamycin Palmitate Hydrochloride in Marketed Drug Products: An Optimization of the Current USP Methodology for Assay. Journal of Analytical Sciences Methods and Instrumentation, 2013, 03, 202-211.	0.1	2
26	The Science and Regulatory Perspectives of Pharmaceutical Suspensions. , 2010, , 265-283.		0
27	Stability of Split Tablets. , 2010, , 153-160.		0